{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:28:05Z","timestamp":1785583685195,"version":"3.56.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,7]]},"DOI":"10.7759\/cureus.83680","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T21:32:26Z","timestamp":1746653546000},"source":"Crossref","is-referenced-by-count":1,"title":["Emphysematous Cystitis in an Immunocompetent Patient on an SGLT2 Inhibitor"],"prefix":"10.7759","author":[{"given":"Kailey N","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipesh R","family":"Bista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e3181adf18c","article-title":"Emphysematous cystitis in the absence of known risk factors: an unusual clinical entity","volume":"102","author":"Kelesidis T","year":"2009","unstructured":"Kelesidis T, Osman S, Tsiodras S. Emphysematous cystitis in the absence of known risk factors: an unusual clinical entity. South Med J. 2009, 102:942-6. 10.1097\/SMJ.0b013e3181adf18c","journal-title":"South Med J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1308\/rcsann.2022.0020","article-title":"Emphysematous cystitis: an incidental finding with varying outcomes","volume":"105","author":"Tan TJ","year":"2023","unstructured":"Tan TJ, Parmar K, Mukherjee A, Sonawane P, Badrakumar C. Emphysematous cystitis: an incidental finding with varying outcomes. Ann R Coll Surg Engl. 2023, 105:87-90. 10.1308\/rcsann.2022.0020","journal-title":"Ann R Coll Surg Engl"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)37736-4","article-title":"Mixed acid fermentation of glucose as a mechanism of emphysematous urinary tract infection","volume":"146","author":"Huang JJ","year":"1991","unstructured":"Huang JJ, Chen KW, Ruaan MK. Mixed acid fermentation of glucose as a mechanism of emphysematous urinary tract infection. J Urol. 1991, 146:148-51. 10.1016\/s0022-5347(17)37736-4","journal-title":"J Urol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3180307c3a","article-title":"Emphysematous cystitis: illustrative case report and review of the literature","volume":"86","author":"Grupper M","year":"2007","unstructured":"Grupper M, Kravtsov A, Potasman I. Emphysematous cystitis: illustrative case report and review of the literature. Medicine (Baltimore). 2007, 86:47-53. 10.1097\/MD.0b013e3180307c3a","journal-title":"Medicine (Baltimore)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.06930.x","article-title":"Emphysematous cystitis: a review of 135 cases","volume":"100","author":"Thomas AA","year":"2007","unstructured":"Thomas AA, Lane BR, Thomas AZ, Remer EM, Campbell SC, Shoskes DA. Emphysematous cystitis: a review of 135 cases. BJU Int. 2007, 100:17-20. 10.1111\/j.1464-410X.2007.06930.x","journal-title":"BJU Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/UA.UA_61_20","article-title":"Emphysematous cystitis: a case report and literature review of 113 cases","volume":"13","author":"Ranjan SK","year":"2021","unstructured":"Ranjan SK, Navriya SC, Kumar S, Mittal A, Bhirud DP. Emphysematous cystitis: a case report and literature review of 113 cases. Urol Ann. 2021, 13:312-5. 10.4103\/UA.UA_61_20","journal-title":"Urol Ann"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025, 48:S181-206. 10.2337\/dc25-S009","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.01.040","article-title":"Genitourinary tract infections in patients taking SGLT2 inhibitors: JACC review topic of the week","volume":"83","author":"Kittipibul V","year":"2024","unstructured":"Kittipibul V, Cox ZL, Chesdachai S, Fiuzat M, Lindenfeld J, Mentz RJ. Genitourinary tract infections in patients taking SGLT2 inhibitors: JACC review topic of the week. J Am Coll Cardiol. 2024, 83:1568-78. 10.1016\/j.jacc.2024.01.040","journal-title":"J Am Coll Cardiol"},{"key":"ref9","unstructured":"U.S. Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. (2015). Accessed: February 21, 2025: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-...."},{"key":"ref10","unstructured":"U.S. Food and Drug Administration. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. (2018). Accessed: February 21, 2025: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-occurrences-serious-infection-genital-are...."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/nep.14167","article-title":"Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries - an expert consensus statement","volume":"28","author":"Liew A","year":"2023","unstructured":"Liew A, Lydia A, Matawaran BJ, Susantitaphong P, Tran HT, Lim LL. Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries - an expert consensus statement. Nephrology (Carlton). 2023, 28:415-24. 10.1111\/nep.14167","journal-title":"Nephrology (Carlton)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-023-03339-3","article-title":"UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease 2023 update","volume":"24","author":"Roddick AJ","year":"2023","unstructured":"Roddick AJ, Wonnacott A, Webb D, et al.. UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease 2023 update. BMC Nephrol. 2023, 24:310. 10.1186\/s12882-023-03339-3","journal-title":"BMC Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2022.04.002","article-title":"Emphysematous cystitis and urinary retention in a male patient with diabetes mellitus type 2 treated with empagliflozin","volume":"8","author":"Brock GM","year":"2022","unstructured":"Brock GM, Lane SM, Roosevelt TS. Emphysematous cystitis and urinary retention in a male patient with diabetes mellitus type 2 treated with empagliflozin. AACE Clin Case Rep. 2022, 8:163-5. 10.1016\/j.aace.2022.04.002","journal-title":"AACE Clin Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357405-emphysematous-cystitis-in-an-immunocompetent-patient-on-an-sglt2-inhibitor","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T21:32:28Z","timestamp":1746653548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357405-emphysematous-cystitis-in-an-immunocompetent-patient-on-an-sglt2-inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.83680","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}